Navigation Links
Understanding Chronic Infections May Help in Developing Therapeutic Vaccines

Vaccines for prophylaxis are well known. Famous vaccines include the ones against tetanus, polio, diphtheria, measles, // mumps etc.; Therapeutic vaccines to cure a condition are more recent innovation. The current vaccines tested in this area include the ones against HIV and hepatitis. The therapeutic vaccines aim to enhance the immune system's ability to combat an infectious agent, such as a virus. Now Researchers are also developing therapeutic vaccines to treat a variety of cancers.

But no dramatic progress has been made in this field. However now, scientists in a recent publication in the Journal of Virology from Wistar Institute and Emory University have shown details about what may prevent the immune system from responding effectively to a therapeutic vaccine during a state of chronic infection. Their findings suggest how scientists might alter therapeutic vaccination approaches to make the immune system respond better.

"In this study, we wanted to look at why therapeutic vaccines are generally less effective than prophylactic vaccines," says E. John Wherry, Ph.D., assistant professor in Wistar's Immunology Program and lead author of the study. Wherry conducted the research as a postdoctoral fellow in the Emory University laboratory of Rafi Ahmed, Ph.D., before joining Wistar earlier this year. "What we found was that the T cells in the chronically infected mice responded poorly to the vaccine."

Specifically, Wherry says, the T cells failed to proliferate, or expand in number. This failure to proliferate seemed to correlate with a high viral load, which suggests several directions researchers might pursue in improving response to therapeutic vaccines.

"The ongoing stimulus to the immune system that occurs in chronic infection seems to prevent the immune cells from responding optimally to a therapeutic vaccine," Wherry says. "If we could lower viral load before therapeutic vaccination, we might be able to impro ve efficacy."

The next step for the research, Wherry says, will be to combine therapeutic vaccines with other modalities that either lower viral load or enhance T cell function, particularly the proliferative capacity of T cells. Possible examples include anti-virals that could be given prior to therapeutic vaccination, or a cytokine that might boost the proliferation or survival of responding cells. While Wherry's primary interest is in chronic infection, he notes that research in this area should inform the design of better therapeutic cancer vaccines as well because many of the deficiencies in immune response are similar whether the antigen confronting the immune system is a virus or a tumor.

Extracts of the news from - http://www.eurekalert.org
'"/>




Related medicine news :

1. Understanding The Predictors Of Prostate Cancer
2. Understanding Restless Legs Syndrome
3. Understanding Lung Cancer Metastasis
4. Understanding The Link Between Hormone Replacement and Respiratory Disease
5. Understanding The Risks Of Hormone Therapy
6. Understanding The Link Between Metabolic Syndrome And Drinking Patterns
7. A Better Understanding Of The Brain Network
8. Understanding The Predictor’s Of Alzheimer’s Diseae
9. Understanding The Harmful Effects Of Radiation Exposure
10. Understanding The Origin Of Tumors
11. Understanding Insulin Resistance
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/27/2017)... Jacksonville, Florida (PRWEB) , ... April 27, 2017 , ... ... qualified candidates. But they will rapidly reject an outdated healthcare executive resume. , “If ... good look at your executive resume and wondering if it’s as ready as you ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... North American CAREGiverSM of the Year for her extraordinary compassion and lifelong dedication ... 60,000 North American professional caregivers for the prestigious award each year – identifying ...
(Date:4/27/2017)... ... ... Offering the purest product of its kind, Swissx Labs AG has launched ... the market has seen before. Swissx uses proprietary strains of hemp plants grown in ... for extraction, to produce its CBD oil--maximizing its benefits for health and wellness. Learn ...
(Date:4/26/2017)... ... April 26, 2017 , ... Jump Technologies, Inc., an ... it has completed a round of funding to accelerate its growth strategies. The ... Granite Capital is a growth equity firm focused on investments in healthcare and ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... to announce the ATA 2017 President’s Awards recipients, comprised of organizations and ... healthcare delivery. , The ATA 2017 President’s Awards recognize individuals and ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... CRH) (NYSE MKT: CRHM) (the "Company"), announces that it will participate ... the Sheraton Hotel in Toronto, Ontario . ... is scheduled to present on Tuesday, May 2 at 10:00 am. ... the Board, Tony Holler will also attend the event. ... For more details about the ...
(Date:4/19/2017)... Global Surgical Drainage Device Market: Overview ... remove excess liquid and air. The fluid to be ... lymph. Surgical drains are used in a wide variety ... cardiovascular surgery, neurosurgery, plastic surgery etc. Common use of ... of fluid e.g. blood or pus. Surgical drains are ...
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
Breaking Medicine Technology: